This document discusses recent advances in the diagnosis and management of hepatitis B and chronic hepatitis C. It covers the pathogenesis, diagnosis, and treatment of hepatitis B virus (HBV) infection including HBV genotypes, phases of chronic HBV infection, evaluation of HBsAg-positive patients, molecular diagnosis of HBV, screening for hepatocellular carcinoma, antiviral treatment options, and guidelines for treatment. It also discusses hepatitis C virus infection including acute and chronic hepatitis C, HCV genotypes and structures, evaluation of patients, and treatment recommendations.
ASSIGNMENT ON NEW DISCOVERIES ABOUT HEPATITIS C
HERE I EXPLAIN YOU ABOUT
INTRODUCTION HISTORY SYMPTOMS DIGNOSIS TREATMENTPREVENTIONdiscoveries about hepatitis c in 2020
WHAT IS HEPATITIS C ?
The hepatitis C virus is a small, enveloped, positive-sense single-stranded RNA virus The hepatitis C virus is the cause of hepatitis C and some cancers such as liver cancer and lymphomas in humans. Scientific name: Hepacivirus: hepatitis c virusFamily: FlaviviridaeKingdom: OrthornavirAE
HISTORY
Hepatitis C was first discovered in the 1980s when it became apparent that there was a new virus (not hepatitis A or B) causing liver damage. Before being properly identified in 1989 it was originally known as non-A non-B hepatitis. In 1991 a screening process was developed making it possible to detect HCV in blood samples.
The credit of discovery of HCV goes to Michael Houghton, Harvey Alter, and Charles Rice for which they are awarded 2020 Nobel Prize in Medicine.
Hepatitis C is a blood-borne virus that predominantly infects the cells of the liver. This can result in inflammation and significant damage to the liver. It can also affect the liver’s ability to perform its essential functions. Although it has always been regarded as a liver disease - ‘hepatitis’ means ‘inflammation of the liver’ - recent research has shown that the hepatitis C virus (HCV) affects a number of other areas of the body. These can include the digestive system, the lymphatic system, the immune system and the brain.
SYMPTOMS
Following initial infection, approximately 80% of people do not exhibit any symptoms. Those who are acutely symptomatic may exhibit fever, fatigue, decreased appetite, nausea, vomiting, abdominal pain, dark urine, pale faeces, joint pain and jaundice (yellowing of skin and the whites of the eyes).
DIAGNOSIS
HCV infection is diagnosed in 2 steps: Testing for anti-HCV antibodies with a serological test identifies people who have been infected with the virus. If thantibodiese test is positive for anti-HCV, a nucleic acid test for HCV ribonucleic acid (RNA) is needed to confirm chronic infection and the need for treatment.
TREATMENT
Hepatitis C medicines
Hepatitis C is treated using direct-acting antiviral (DAA) tablets.
DAA tablets are the safest and most effective medicines for treating hepatitis C.
They're highly effective at clearing the infection in more than 90% of people.
The tablets are taken for 8 to 12 weeks. The length of treatment will depend on which type of hepatitis C you have.
Some types of hepatitis C can be treated using more than 1 type of DAA.
NHS-approved hepatitis C medicines include:
HARVONI
sofosbuvir
a combination of ledipasvir and sofosbuvir
a combination of ombitasvir, paritaprevir and ritonavir
Ribavirin ETC.
PREVENTION
There is no vaccine to prevent hepatitis C. The best way to prevent hepatitis C is by avoiding behaviors that can spread the disease, especially injecting drugs with non-sterile injection equipment.
ASSIGNMENT ON NEW DISCOVERIES ABOUT HEPATITIS C
HERE I EXPLAIN YOU ABOUT
INTRODUCTION HISTORY SYMPTOMS DIGNOSIS TREATMENTPREVENTIONdiscoveries about hepatitis c in 2020
WHAT IS HEPATITIS C ?
The hepatitis C virus is a small, enveloped, positive-sense single-stranded RNA virus The hepatitis C virus is the cause of hepatitis C and some cancers such as liver cancer and lymphomas in humans. Scientific name: Hepacivirus: hepatitis c virusFamily: FlaviviridaeKingdom: OrthornavirAE
HISTORY
Hepatitis C was first discovered in the 1980s when it became apparent that there was a new virus (not hepatitis A or B) causing liver damage. Before being properly identified in 1989 it was originally known as non-A non-B hepatitis. In 1991 a screening process was developed making it possible to detect HCV in blood samples.
The credit of discovery of HCV goes to Michael Houghton, Harvey Alter, and Charles Rice for which they are awarded 2020 Nobel Prize in Medicine.
Hepatitis C is a blood-borne virus that predominantly infects the cells of the liver. This can result in inflammation and significant damage to the liver. It can also affect the liver’s ability to perform its essential functions. Although it has always been regarded as a liver disease - ‘hepatitis’ means ‘inflammation of the liver’ - recent research has shown that the hepatitis C virus (HCV) affects a number of other areas of the body. These can include the digestive system, the lymphatic system, the immune system and the brain.
SYMPTOMS
Following initial infection, approximately 80% of people do not exhibit any symptoms. Those who are acutely symptomatic may exhibit fever, fatigue, decreased appetite, nausea, vomiting, abdominal pain, dark urine, pale faeces, joint pain and jaundice (yellowing of skin and the whites of the eyes).
DIAGNOSIS
HCV infection is diagnosed in 2 steps: Testing for anti-HCV antibodies with a serological test identifies people who have been infected with the virus. If thantibodiese test is positive for anti-HCV, a nucleic acid test for HCV ribonucleic acid (RNA) is needed to confirm chronic infection and the need for treatment.
TREATMENT
Hepatitis C medicines
Hepatitis C is treated using direct-acting antiviral (DAA) tablets.
DAA tablets are the safest and most effective medicines for treating hepatitis C.
They're highly effective at clearing the infection in more than 90% of people.
The tablets are taken for 8 to 12 weeks. The length of treatment will depend on which type of hepatitis C you have.
Some types of hepatitis C can be treated using more than 1 type of DAA.
NHS-approved hepatitis C medicines include:
HARVONI
sofosbuvir
a combination of ledipasvir and sofosbuvir
a combination of ombitasvir, paritaprevir and ritonavir
Ribavirin ETC.
PREVENTION
There is no vaccine to prevent hepatitis C. The best way to prevent hepatitis C is by avoiding behaviors that can spread the disease, especially injecting drugs with non-sterile injection equipment.
NAFLD is a vast topic and recently gaining a lot of importance. Fatty liver, NASH, are other topics discussed here. sleissenger, sheila sherlock and Harrisons are used for reference
NAFLD is a vast topic and recently gaining a lot of importance. Fatty liver, NASH, are other topics discussed here. sleissenger, sheila sherlock and Harrisons are used for reference
viral markers in diagnosis monitoring and treatment of hepatitis b and c.pptxPathKind Labs
Hepatitis B Virus and Hepatitis C Virus infections are transmitted by parentral route. Early diagnosis and treatment can prevent cirrhosis of liver in HCV cases as drugs which can cure the infection are now available.
Introduction to chronic Hepatitis B Infection in Malaysia, epidemiology and common treatment. Phases of chronic Hepatitis B Infection, clinical presentation and complications.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
3. oHepatitis B is an infectious disease caused by the Hepatitis B virus
(HBV).
oIt is a major public health problem, causing chronic hepatitis, cirrhosis
of liver and hepatocellular carcinoma.
oHuman carcinogen—cause of up to 80% of hepatocellular
carcinomas.
10. • Appears in the blood about 6 weeks after infection and has usually
disappeared by 3 months after the clinical illness.
• Persistence for more than 6 months implies the development of a
carrier state or progression to chronicity
• A diagnosis of HBV infection can usually be made by detection of
HBsAg in serum
11. • An inverse correlation exists between the serum concentration of
HBsAg and the degree of liver cell damage.
• These suggest that, in hepatitis B, the degree of liver cell damage and
the clinical course are related to variations in the patient’s immune
response to HBV rather than to the amount of circulating HBsAg
13. • HBeAg has a signal peptide that binds it to the smooth endoplasmic
reticulum, the secretory apparatus of cell, leading to its secretion into
circulation.
• This secreted nucleocapsid protein is thus a reliable qualitative
marker of HBV replication and infectivity
• HBcAg, devoid of signal peptide is not secreted and incorporated into
nucleocapsid.
14. HBxAg
• Capable of transactivating the transcription of both viral and cellular
genes
• clinical association observed between the expression of HBxAg and
antibodies to it in patients with severe chronic hepatitis and
hepatocellular carcinoma
• The transactivating activity can enhance the transcription and
replication of other viruses besides HBV such as HIV.
21. Phase Liver histology
Immune Tolerant Minimal inflammation and fibrosis
Immune Clearance Moderate to severe inflammation or
fibrosis
Inactive Disease Minimal necroinflammation but variable
fibrosis
HBeAg-negative Chronic HBV Moderate to severe inflammation or
fibrosis
22. Evaluation of HBsAg +ve patients
• HISTORY
Symptoms and signs of liver disease
alcohol and metabolic risk factors
Family history of HCC
vaccination status
24. SEROLOGY/ VIROLOGY
• HBsAg quantitative assay - The quantitative
electrochemiluminescence immunoassay determines the HBsAg
levels expressed in IU/mL
• widely used to monitor chronic Hepatitis B (CHB) patients response to
antiviral Therapy.
25. Antibodies to HBc
• In patients with hepatitis B surface antigenemia of unknown duration
testing for IgM anti-HBc may be useful to distinguish between acute
or recent infection (IgM anti-HBc-positive) and chronic HBV infection
• Specificity = 99.8% to 99.9%
26. HBeAg
• HBeAg correlates with ongoing viral synthesis and with infectivity
• Persistence for more than 10 weeks strongly suggests the
development of chronicity
27. Anti HBe
• Prognostic for resolution of infection
• The appearance of Anti-Hbe is strong evidence that the patient will
recover completely.
28. Anti HBs
• After immunization with hepatitis B vaccine, which consists of HBsAg
alone, anti-HBs is the only serologic marker to appear
• Anti-HBs >12mIu – Protective
29.
30. Molecular Advances in Diagnosis of HBV
Infection
• Current HBV DNA assays make use of differing technologies and can
generally divided into i) signal amplification assays
ii) DNA amplification tests based on PCR
• HBV DNA detection based on PCR approach can detect as few as 10 2
– 10 3 Genome copies
31. HBV DNA
• the most sensitive index of viral replication.
• It is a good marker of the level of viraemia, can be correlated with
serum transaminase levels
32. NEEDLE LIVER BIOPSY
• ascertain the degree of necroinflammation and fibrosis
• help guide the decision to treat.
• the amount of replicating virus in the serum does not correlate with
the degree of histological activity
36. • In a meta-analysis of 40 studies, investigators concluded that an APRI
score greater than 1.0 had a sensitivity of 76% and specificity of 72%
for predicting cirrhosis
38. FIB-4 score <1.45 had a negative predictive value of 90% for
advanced fibrosis.
FIB-4 >3.25 would have a 97% specificity and a positive
predictive value of 65% for advanced fibrosis.
these individuals could potentially have avoided liver biopsy.
39. Fibroscan
• measure liver stiffness
• based on ultrasound technology.
• Transient elastography performed with FibroScan has been the most widely
evaluated.
• >90% accuracy for early Fibrosis and Cirrhosis.
• Cost in India – Rs.4000 to 5000/- per scan.
40.
41. Screening for HCC
oPatients who are HBsAg positive with chronic hepatitis or cirrhosis,
especially if male and more than 45 years old, should be screened
regularly so that hepato-cellular carcinoma may be diagnosed early
when surgical resection may prove possible.
oSerum α-fetoprotein should be measured and ultrasound
examination performed at 6-monthly intervals.
42. • HBsAg seroclearance did not reduce therisk of HCC in patients with
Hepatitis B
• Hepatitis B patients who have indications for surveillance pre
seroclearance should continue getting surveillance post
seroclearance.
P pP Gounder, Bulkow, Snowball et al; Nested case control study:
Hepatocellular carcinoma risk after Hepatitis B surface antigen
seroclerance
44. ACUTE HEPATITIS B
• Supportive management
• Recovery in 99% cases
• Severe acute Hepatitis B – antiviral therapy with nucleoside analogue
duration – until 3 months after HBsAg seroconversion or
6months after HBeAg seroconversion
46. INTERFERONS
• Interferon alpha was the first approved therapy for chronic Hepatitis
B.
Mechanisms – immunostimulatory
intrinsic antiviral activity
• Dosage – 5million units daily or
10million units thrice a week
48. • Complications – flu like symptoms
marrow suppression
emotional lability
autoimmune reactions
alopecia, rashes, diarrhoea
numbness and tingling
49. PEGYLATED INTERFERONS
• Polyethylene glycol (PEG) is added to make interferon last longer in
the body
• Ease of administration
• Higher efficacy
• Better sustained response rate
51. LAMIVUDINE
• Clinical and laboratory side effects of lamivudine are negligible
• Emergence of resistance
• Long-term monotherapy with lamivudine is associated with
methionine to valine(M204V) or methionine-to-isoleucine
(M2041)mutations, primarily at amino acid 204 in the tyrosine-
methionine aspartate-aspartate (YMDD) motif of HBV DNA
polymerase
52. • lamivudine is no longer recommended as first-line therapy
• The drug is still used widely as first-line therapy in developing
countries
53. ADEFOVIR DIPIVOXIL
• effective against both wild-type and lamivudine-resistant HBV.
• primary treatment failure (<1 log decline in the serum HBV DNA level
at week 12) was observed in 30% of patients
• Adverse effect – nephrotoxicity
• Dose – 10mg/day
54. • No longer recommended as a first line therapy
• Used widely as primary therapy or in combination with lamivudine in
resistant cases.
55. TENOFOVIR
• More potent agent
• Dosage – 300mg/day
• Active against wild type HBV
lamivudine resistant HBV
slow or limited response to adefovir
56. • The 5-year safety and resistance profile are very favourable
• Replaced adefovir both as first line therapy for chronic Hepatitis B and
add on therapy for lamivudine resistant cases.
57. • Tenofovir monotherapy was as effective as tenofovir emtricitabine
combination and well tolerated in Lamivudine resistans chronic
hepatitis B patients for upto 240 weeks
Fung s, Kwan P, Fabri M et al; TDF versus TDF/FTC in Lamivudine
resistant Hepatitis B : a 5yr randomised study. J.Hepatology 2016
Aug18.
58. ENTECAVIR
• The most potent of the HBV antivirals
• High potency and high barrier to resistance renders it a first line drug
for patients with chronic Hepatits B
• Resistance to entecavir in lamivudine resistant chronic hepatitis B has
been recorded to increase progressively to 43% at 4 years.
• Entecavir is not as attractive a choice as adefovir or tenofovir for
patients with lamivudine resistant hepatitis B
60. GUIDELINES
1. AASLD: American Association of Study of Liver Diseases
2. EASL: European Association for the Study of Liver
3. WHO: World Health Organization
61. TREATMENT RECOMMENDATIONS
• All adults, adolescents and children with CHB and clinical evidence of
compensated or decompensated cirrhosis should be treated,
regardless of ALT levels, HBeAg status or HBV DNA levels
62. • Treatment is recommended for adults with CHB who do not have
clinical evidence of cirrhosis but are aged more than 30 years have
persistently abnormal ALT levels with evidence of high-level HBV
replication (HBV DNA >20 000 IU/mL), regardless of HBeAg status
63. • Antiviral therapy is not recommended and can be deferred in persons
without clinical evidence of cirrhosis and with persistently normal ALT
levels and low levels of HBV replication (HBV DNA <2000 IU/mL),
regardless of HBeAg status or age
64. Continued monitoring is necessary
• persons without cirrhosis aged 30 years or less, with HBV DNA levels
>20 000 IU/ mL but persistently normal ALT
• HBeAg-negative persons without cirrhosis aged 30 years or less, with
HBV DNA levels that fluctuate between 2000 and 20 000 IU/mL, or
who have intermittently abnormal ALT levels
65.
66.
67.
68. TREATMENT OF HEPATITIS B IN INDIA
• Guidelines recommend selection of drugs with high potency and low
risk of resistance
• Most guidelines advocate initial treatment with ETV, TDF or peg-IFN
• There is insufficient safety and efficacy data on antiviral agents in
India
69. • ETV has been associated with significantly higher rates of serological,
viral and biochemical improvement with no resistance
• ADV was found to be less potent though the frequency of resistance
mutations was low
• TDF and LdT were reported to reverse decompensation and improve
hepatic functional status with significant reduction in HBV DNA levels
70. • Though all approved agents are available in India, treatment with
guideline recommended first-line agents is a challenge, the major
hurdle being unaffordability due to high cost of therapy
72. • ETV, LdT and TDF can be recommended in compliant patients who
can afford good treatment
• LAM/ADV combination may be advised for non-affording patients
with well compensated cirrhosis while LAM alone may be advised in
those with grade II fibrosis.
73. When to stop treatment?
• Lifelong NA therapy : All persons with clinical evidence of Cirrhosis.
74. • Discontinuation and careful long term follow up in :
oPersons without clinical evidence of cirrhosis
oEvidence of HBeAg loss and seroconversion to anti-HBe after
completion of atleast 1 year of treatment.
oIn association with persistently normal ALT levels and persistently
undetectable HBV DNA levels
75. LIVER TRANSPLANTATION
• Liver transplantation is currently a successful therapy for end-stage
chronic HBV-associated liver disease.
• The use of high dose HBIG ( Hepatitis B immunoglobulin ) peri-
operatively and post-operatively, combined with treatment of heptitis
B with entecavir or tenofovir are favored to prevent recurrent HBV
infection post-transplantation.
76. Special Groups : HBV-HIV coinfection
• treating for both HBV and HIV is recommended.
• Lamivudine, Emtricitabine and Tenofovir are all nucleoside analogs
with activity against both HIV and HBV
• Rate of HBV resistance to Lamivudine in HBV-HIV coinfection is almost
90% at 4 years, hence lamivudine should never be used as
monotherapy
77. • Entecavir has low-level activity against HIV and can result in selection
of HIV resistance
• Tenofovir and the combination of tenofovir and emtricitabine in one
pill are approved therapies for HIV and represent excellent choices for
treating HBV infection in HBV-HIV co-infected patients
78. PREGNANCY
• Tenofovir is effective in reducing mother to child transmission
Calvin Q Pan, Erhei Dai et al; Tenofovir to prevent Hepatitis B
transmission in mothers with high viral load, N Engl J Med 2016 June
16,; 2324-2334
79. CHB on Cytotoxic Chemotherapy
• Preemptive treatment with anti-virals for 6 months for inactive
Hepatitis B carriers prior to the initiation of chemotherapy has been
shown to reduce the risk of such reactivation.
80. PREVENTION & IMMUNOPROPHYLAXIS
• Hepatitis B immunoglobulin (HBIG) :
effective for passive immunization if given prophylactically or within
hours of infection.
It is indicated for sexual contacts of acute sufferers, babies born to
HBsAg-positive mothers and victims of parenteral exposure (needle
stick) to HBsAg-positive blood.
81. oIn healthy individuals the recombinant vaccine is given in a dose of
20μg (2 ml) intramuscularly, repeated at 1 month with a booster at 6
months.
oFor patients undergoing haemodialysis and for other
immunosuppressed patients, higher vaccine dosages (40μg) or an
increased number of doses are recommended(4 doses).
82. POST EXPOSURE PROPHYLAXIS
• 0.06ml/Kg HBIG plus first dose of Hepatitis B Vaccine and continue
vaccine course.
84. • Family – Flaviviridae
• Genus – Hepacivirus
• A small ( 50 nm ) virus ss RNA virus
• RNA sequence analysis into at least six major genotypes (Clades)
• There are 100 subtypes.
85.
86. • HCV circulates in various forms in the serum of an infected host,
including
(1) virions that are bound to very-low-density and low-density
lipoproteins and appear to represent the infectious fraction,
(2) virions bound to immunoglobulins
(3) free virions.
87. • Chronic hepatitis develops in 50% to 90% of persons with acute HCV
infection.
• In the minority of patients in whom acute HCV resolves, an early and
multispecific T-cell response occurs.
• This response can be detected up to 20 years after resolution of
infection and may contribute to protection in case of subsequent
exposures to HCV.
88. ACUTE HEPATITIS C
• Acute hepatitis C is rarely seen in clinical practice
• nearly all cases are asymptomatic
• Even in symptomatic patients, however, most of the clinical symptoms
are nonspecific
• fatigue, nausea, abdominal pain, loss of appetite, mild fever, itching,
myalgia, Jaundice
89.
90. • The rate of viral persistence after acute infection ranges from 45% to
more than 90%.
Age and gender
source of infection and size of inoculum
immune status of the host
patient’s race
• the rate of spontaneous clearance is higher in symptomatic patients
in whom jaundice develops during acute infection than in those who
remain asymptomatic
91. CHRONIC HEPATITIS C
• Chronic HCV infection has a variable course; in some patients disease
progression to cirrhosis is slow, while in others, progression is more
rapid
92.
93. INVESTIGATIONS
Indirect Assays
• EIAs detect antibodies against different HCV antigens
• The third-generation EIAs detect antibodies against HCV core, NS3,
NS4, and NS5 antigens as early as 7 to 8 weeks after infection, with
sensitivity and specificity rates of 99%
94. • The presence of anti-HCV in high titer in serum (enzyme
immunoassay [EIA] ratio> 9) indicates exposure to the virus
• does not differentiate among acute, chronic, and resolved infection.
• Serologic assays are used initially for diagnosis.
95. Direct Assays
• Virologic assays are required for confirming infection, monitoring
response to treatment, and evaluating immunocompromised
patients.
96. • Quantitative assays
Real time PCR
Transcription meadiated amplification
• The advantages of these very sensitive tests include positivity within 1
to 3 weeks after acute infection and detection of low-level residual
infection during antiviral therapy
• Disadvantage – lack of comparability among different assays
97. • HCV core antigen assay - cheaper and faster alternative
Fully automated immunoassays
98. HCV GENOTYPING
• The most accurate method is PCR methodology and direct sequencing
of the NS5B or E1 region
• Reverse hybridization to genotype-specific probes
• restriction fragment length polymorphism analysis
• PCR amplification of the 5′ noncoding region of the HCV genome.
102. EASL Recommendations
• Anti-HCV antibodies are the first-line diagnostic test for HCV infection
• In the case of suspected acute hepatitis C or in immunocompromised
patients, HCV RNA testing should be part of the initial evaluation
103. • If anti-HCV antibodies are detected, HCV RNA should be determined
by a sensitive molecular method
• Anti-HCV-positive, HCV RNA negative individuals should be retested
for HCV RNA three months later to confirm true convalescence
107. Ribavirin
• Guanosine analogue
• Side effect – RBC breakdown
birth defect in babies
Taribavirin [viramidine or ribamidine] - ribavirin derivative
less erythrocyte-trapping and better liver-targeting than
ribavirin.
phase III human trials
110. EASL Recommendations
• The goal of therapy is to cure HCV infection to prevent hepatic
cirrhosis, decompensation of cirrhosis, HCC, severe extra-hepatic
manifestations and death
• The endpoint of therapy is undetectable HCV RNA in a sensitive assay
(≤15 IU/ml) 12 weeks (SVR12) and 24 weeks (SVR24) after the end of
treatment
111. • In patients with advanced fibrosis and cirrhosis, HCV eradication
reduces the rate of decompensation and will reduce, albeit not
abolish, the risk of HCC. In these patients surveillance for HCC should
be continued
• In patients with decompensated cirrhosis, HCV eradication reduces
the need for liver transplantation. Whether HCV eradication impacts
mid- to long-term survival in these patients is unknown
112. • Treatment is indicated
All treatment-naive and treatment-experienced patients with
compensated and decompensated liver disease
113. Treatment should be prioritized
• Patients with significant fibrosis (F3) or cirrhosis (F4), including
decompensated cirrhosis
• Patients with HIV coinfection
• Patients with HBV coinfection
• Patients with an indication for liver transplantation
114. • Patients with HCV recurrence after liver transplantation
• Patients with clinically significant extra-hepatic manifestations
• Patients with debilitating fatigue
• Individuals at risk of transmitting HCV (active injection drug users,
men who have sex with men with high-risk sexual practices, women
of child-bearing age who wish to get pregnant, haemodialysis
patients, incarcerated individuals)
115. Treatment can be deferred
Patients with no or mild disease (F0-F1) and none of
the above-mentioned extrahepatic manifestations
116. Treatment is not recommended
Patients with limited life expectancy due to non-liver
related comorbidities
117. HCV genotype 1
• a combination of weekly PegIFN-α, daily weightbased ribavirin (1000
or 1200 mg in patients <75 kg or ≥75 kg, respectively), and daily
sofosbuvir (400 mg) 12 weeks
118. • combination of weekly PegIFN-α, daily weightbased ribavirin (1000 or
1200 mg in patients <75 kg or ≥75 kg, respectively), and daily
simeprevir (150 mg) for 12 weeks to be followed bg PegIFN and
ribavirin for 12weeks
119. IFN free regimens
• Sofosbuvir (400 mg) and ledipasvir (90 mg)
• sofosbuvir (400 mg) and simeprevir (150 mg)
• sofosbuvir (400 mg) and daclatasvir (60 mg)
120. • Duration - 12 weeks
• Patients with cirrhosis - with daily weight-based ribavirin
• If ribavirin contraindicated - combination for 24 weeks
121. • the fixed-dose combination of ombitasvir (12.5 mg), paritaprevir (75
mg) and ritonavir (50 mg) in one single tablet (two tablets once daily
with food), and dasabuvir (250 mg) (one tablet twice daily)
122. • 1a with cirrhosis – 24weeks with ribavirin
• 1a without cirrhosis – 12weeks with ribavirin
• 1b without cirrhosis – 12weeks without ribavirin
• 1b with cirrhosis – 12weeks with ribavirin
123. HCV genotype 2
• daily weight-based ribavirin (1000 or 1200 mg in patients <75 kg or
≥75 kg, respectively), and daily sofosbuvir (400 mg) for 12 weeks
• Cirrhosis or treatment experienced – 16-20 weeks
124. Cirrhotic and/or treatment-experienced
patients
• weekly PegIFN-α, daily weight-based ribavirin (1000 or 1200 mg in
patients <75 kg or ≥75 kg, respectively), and daily sofosbuvir (400 mg)
12 weeks
• an IFN-free combination of daily sofosbuvir (400 mg) and daily
daclatasvir (60 mg) for 12 weeks
125. HCV genotype 3
• weekly PegIFN-α, weightbased ribavirin (1000 or 1200 mg in patients
<75 kg or ≥75 kg, respectively), and sofosbuvir (400 mg) daily 12
Weeks
• weight-based ribavirin (1000 or 1200 mg in patients <75 kg or ≥75 kg,
respectively) sofosbuvir (400 mg) daily for 24 weeks
• sofosbuvir (400 mg) and daclatasvir (60 mg) daily for 12weeks
126. HCV genotype 4
• a combination of weekly PegIFN-α, daily weightbased ribavirin (1000
or 1200 mg in patients <75 kg or ≥75 kg, respectively), and daily
sofosbuvir (400 mg) 12 weeks
127. • combination of weekly PegIFN-α, daily weightbased ribavirin (1000 or
1200 mg in patients <75 kg or ≥75 kg, respectively), and daily
simeprevir (150 mg) for 12 weeks to be followed bg PegIFN and
ribavirin for 12weeks
128. HCV genotype 5 or 6
• a combination of weekly PegIFN-α, daily weightbased ribavirin (1000
or 1200 mg in patients <75 kg or ≥75 kg, respectively), and daily
sofosbuvir (400 mg) 12 weeks
129. IFN free regimens for HCV genotype 4/5/6
• Sofosbuvir (400 mg) and ledipasvir (90 mg)
• sofosbuvir (400 mg) and simeprevir (150 mg)
• sofosbuvir (400 mg) and daclatasvir (60 mg)
130. • Duration - 12 weeks
• Patients with cirrhosis - with daily weight-based ribavirin
• If ribavirin contraindicated - combination for 24 weeks
131. Monitoring therapy
• PegIFN-α and ribavirin – Haematological parameters
• Sofusbuvir – Renal function tests
• Simprevir – rashes and indirect bilirubin
132.
133. • A real-time PCR-based assay with a lower limit of detection of ≤15 IU/ml
should be used to monitor HCV RNA levels during and after therapy
• PegIFN-α, ribavirin and sofosbuvir - at baseline and at weeks 4, 12 (end of
treatment), and 12 or 24 weeks after the end of therapy
• PegIFN-α, ribavirin and simeprevir - at baseline, week 4, week 12, week 24
and 12 or 24 weeks after the end of therapy
• IFN-free regimen - at baseline, week 2 (assessment of adherence), week 4,
end of treatment and 12 or 24 weeks after the end of therapy
134. • Success of the treatment is assessed by SVR – defined as absence of
detectable HCV RNA in the serum six months following end of
treatment
• Relapsers: are defined as patients who achieved undetectable HCV
RNA at the end of treatment and subsequently relapsed and did not
achieve SVR
135. • With the triple combination of PegIFN-α, ribavirin and simeprevir,
treatment should be stopped if HCV RNA level is ≥25 IU/ml at
treatment week 4, week 12 or week 24
• An immediate switch to another IFN-containing DAA containing or to
an IFN-free regimen without a protease inhibitor should be
considered
136.
137.
138.
139. HBV HCV COINFECTION
• Patients should be treated with the same regimens, following the
same rules as HCV monoinfected patients
• If HBV replicates at significant levels before, during or after HCV
clearance, concurrent HBV nucleoside/ nucleotide analogue therapy
is indicated
140. POST TRANSPLANT INFECTION
• All patients with post-transplant recurrence of HCV infection should
be considered for therapy
• an IFN-free regimen, for 12 or 24 weeks with ribavirin
141. In hemodialysis patients
• Haemodialysis patients should be considered for antiviral therapy
• an IFN-free, if possible ribavirin-free regimen, for 12 weeks in patients
without cirrhosis, for 24 weeks in patients with cirrhosis
• Sofosbuvir should not be administered to patients with an eGFR <30
ml/min/1.73 m2 or with end-stage renal disease
142. HCV HIV COINFECTION
• Regardless of genotype
• Weekly PEG IFN plus daily ribavirin
• Duration - 48 weeks
145. Hepatitis C in India
• According to current estimates more than 6 million people are
affected with Hepatitis C in India
• The predominant genotypes of HCV in India are genotype 3, followed
by genotype 1 and genotypes 4
• Until recently PEG IFN and ribavirin was the only treatment available
in India which costs around Rs.6000 per week
146. • Generic versions of sofosbuvir, ledipasvir and daclatasvir have now
become available in India, reducing the cost of therapy
• Combination therapy with ledipasvir and sofosbuvir or daclatasvir and
sofosbuvir with or without ribavirin is much more affordable than the
earlier treatment with PEG-IFNbased therapy
147. • Harvoni, the fixed-dose combination of ledipasvir-sofosbuvir of 90mg
and 400mg, respectively - Rs.25,000 for a bottle of 28 tablets.
• Sofusbuvir tablets – Rs 17000 for a bottle of 28 tablets
• Daclatasavir – Rs.3500 for 28 tablets
• Epclusa – sofusbuvir and velpatasavir
148. WHO organizes World Hepatitis day on 28 July
every year to increase awareness and
understanding of viral Hepatitis
149. REFERENCES
• Harrison’s Principles of Internal Medicine 19th Edition
• Sleisinger and Fordtran’s Gastrointestinal and liver diseases 10th
edition
• Diseases of liver and biliary system Sheila Sherlock 11th edition
• Pawlotsky et al, EASL Recommendations on Treatment of Hepatitis C
2015, Journal of Hepatology 2015 vol. 63 j 199–236
• WHO global guideline for Hepatitis B 2015
The virus was not discovered until 1965 when Baruch Blumberg, discovered the Australia antigen ( later known to be Heptitis B Surface antigen, or HBsAg ) in the blood of Australian aboriginal people.
HBV is a small DNA virus that belongs to the Hepadnaviridae
family.
a DNA genome that has a relaxed, circular, partially double-stranded configuration
Exists in three forms
22nm particles – spherical or long filamentous
42nm particles – double shelled spherical particles
intact hepatitis B virion
The clinical associations with the various genotypes have not led to specific recommendations on routine testing because genotype classification does not generally lead to a difference in management.
The 4 viral genes components include the core, surface, X, and polymerase genes. The core gene encodes the core nucleocapsid protein, which is important in viral packaging and production of HBeAg. The surface gene encodes the pre-S1, pre-S2, and S proteins (comprising the large [L], middle [M], and small [S] surface proteins). The X gene encodes the X protein, which has transactivating properties and may be important in hepatic carcinogenesis. The polymerase gene haS a large ORF (≈800 amino acids) and overlaps the entire length of the surface ORF. It encodes a large protein with functions that are critical for packaging and DNA replication
, titers are highest in immunosuppressed patients, lower in patients with chronic liver disease, and very low in patients with acute fulminant hepatitis.
testing for it is not part of routine
clinical practice.
Persons with chronic HBV infection, by contrast, exhibit infrequent, narrowly focused, and weak HBVspecific T-cell responses
COMMONLY ENCOUNTERED SEROLOGICAL PATTERNS
for assessing the stage of liver disease are supplanting liver biopsy and have been validated in adults with CHB.
Tenofovir or entecavir
Clinical trials have not yet established the efficacy of this.
RECURRENCE RATE IS HIGH BECAUSE OF EXTRAHEPATIC PROLIFERATION
Patients with chronic hepatitis B who undergo cytotoxic chemotherapy for treatment of malignancies experience enhanced HBV replication and viral expression on hepatocyte membranes during chemotherapy coupled with suppression of cellular immunity. Such patients are at risk of reactivation of Hepatitis B.
The 2 envelope
proteins, E1 and E2, heterodimerize and assemble into tetramers,
which create a smooth outer layer
The nucleocapsid is believed to be composed of multiple
copies of the core protein and forms an internal icosahedral
viral coat that encapsulates the genomic RNA
- younger and female patients having the lowest rates of chronicity.
chronicity
may be less common in PWID than in those who acquire
HCV infection by blood transfusion),
chronicity rates are higher in persons with immunodeficiency
states such as agammaglobulinemia and HIV infection
No standardisation
The serology of hepatitis C infection with a chronic
course. Note that HCV RNA appears early, before the rise in
alanine transferase (ALT) and persists. Anti-HCV positivity is
delayed, appearing between 11 and 20 weeks of the onset. ALT
shows characteristic fluctuations as chronicity develops
Nucleoside inhibitor
Epclusa – sofusbuvir and velpatasavir
Patients with decompensated cirrhosis should be urgently treated with ifn free regimen